A phase I trial demonstrated that AFP-specific genetic immunotherapy elicited detectable AFP-reactive cytotoxic T-cell responses in patients with hepatocellular carcinoma, confirming the feasibility and immunogenicity of this approach, although no objective tumor regression was reported [216]. The gene discussed is AFP; the disease is neoplasm.